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N-Myristoyltransferase (NMT) modulates protein
function through the attachment of the lipidmyristate
to the N terminus of target proteins, and is a prom-
ising drug target in eukaryotic parasites such as
Leishmania donovani. Only a small number of NMT
substrates have been characterized in Leishmania,
and a global picture of N-myristoylation is lacking.
Here, we use metabolic tagging with an alkyne-func-
tionalized myristic acid mimetic in live parasites fol-
lowed by downstream click chemistry and analysis
to identify lipidated proteins in both the promastigote
(extracellular) and amastigote (intracellular) life
stages. Quantitative chemical proteomics is used to
profile target engagement by NMT inhibitors, and to
define the complement of N-myristoylated proteins.
Our results provide new insight into the multiple
pathways modulated by NMT and the pleiotropic ef-
fects of NMT inhibition. This work constitutes the first
global experimental analysis of protein lipidation in
Leishmania, and reveals the extent of NMT-related
biology yet to be explored for this neglected human
pathogen.
INTRODUCTION
Over 300 million people are at risk from the leishmaniases, a
spectrum of neglected tropical parasitic diseases strongly asso-
ciated with poverty, which cause around 30,000 deaths annually
(Alvar et al., 2012). The diseases take twomain forms: cutaneous
leishmaniasis (CL), manifesting as skin lesions, and visceral
leishmaniasis (VL), also known as kala-azar, a systemic infection
causing swelling of organs, fever, and anemia, that is almost
invariably fatal if left untreated. The causative agents of these
debilitating diseases are species of the Leishmania protozoan
parasite, a unicellular eukaryote. Leishmania donovani (Ld) is
the principle causative agent of VL while Leishmania major342 Chemistry & Biology 22, 342–354, March 19, 2015 ª2015 The Au(Lm) is themain species responsible for CL. The parasite is trans-
mitted by sand fly vectors, which inoculate the promastigote
forms into the human host. Here, they are taken up by phago-
cytic cells, mainly macrophages, and transform into the obligate
intracellular amastigotes, which then replicate and can infect
other phagocytes. Transmission occurs when a sand fly takes
up infected cells in a blood meal. Inside the sand fly midgut,
amastigotes transform into promastigotes. There are currently
few drugs to treat the leishmaniases, and those that are available
have problems of toxicity, teratogenicity, high cost, difficult
administration, and/or parasite resistance. These drugs work
via nonspecific antibiotic effects, such as disruption of cell mem-
branes, or their mode of action is unknown (Tate et al., 2014).
Novel drugs with a defined mechanism of action, high efficacy
and low toxicity are urgently required to combat these devas-
tating diseases.
The enzyme myristoyl-CoA:protein N-myristoyltransferase
(NMT) has recently been validated as a promising drug target in
trypanosomiasis (Frearson et al., 2010) and malaria (Wright
et al., 2014), diseases caused by the protozoan parasites Trypa-
nosoma brucei and species of Plasmodium, respectively. NMT
has also been proposed as a potential drug target for infections
caused by parasitic nematodes (Galvin et al., 2014) and for the
leishmaniases (Price et al., 2003). NMT catalyzes a protein modi-
fication, the attachment of theC14:0 lipidmyristate (Myr, tetrade-
canoic acid, Figure 1A) to the N-terminal glycine residue of
specific target proteins in the cell. This reaction usually occurs
cotranslationally during ribosomal synthesis of the protein,
affording a stable, amide-linked lipid thatmodulates protein func-
tion, typically promoting protein localization to cellular mem-
branes (Wright et al., 2010). NMT has been characterized in Ld
and Lm and appears to be essential for survival of promastigotes
in both organisms (Brannigan et al., 2010; Price et al., 2003),
although evidence for the importance of NMT in amastigotes
has yet to be reported. Structure-based design and high-
throughput screening has led to the discovery of several distinct
NMT inhibitor series (Bell et al., 2012; Brannigan et al., 2014;
Hutton et al., 2014; Olaleye et al., 2014). Around 60 Leishmania
proteins have been predicted to be N-myristoylated using
bioinformatic approaches based on learning sets from unrelated
organisms (Mills et al., 2007), but experimental evidence has onlythors
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Figure 1. Tagging of Proteins by YnMyr in Leishmania
(A) Overview of metabolic tagging of proteins with myristic acid analog YnMyr and analysis following CuAAC labeling.
(B) YnMyr tagging in L. donovani promastigotes. Following CuAAC labeling with reagent AzTB, samples were precipitated with CHCl3/MeOH (CM) or with MeOH
and then treated with NaOH as indicated. CB, Coomassie blue.
(C) The effect of pronase digestion on tagging. Pronase digests protein resulting in a loss of the discrete fluorescent bands but leaving the diffuse labeling
relatively unaffected.
(D) YnMyr tagging compared with other analogs YnPal and AzMyr in promastigotes. Pal, palmitic acid; Myr, myristic acid. CuAAC capture reagent: Az, AzTB;
Yn, YnTB.
(E) Chemical tools. Additional labeling data are shown in Figure S1.been reported for six; these include ADP-ribosylation factor-like
protein LdARL1 (Sahin et al., 2008), LdARL3A (Cuvillier et al.,
2000), and several proteins that have been shown to carry a
dual N-myristoylation and S-palmitoylation acylation motif. This
latter modification involves the incorporation of hexadecanoic
acid or other long chain fatty acids via a thioester linkage at a
cysteine side chain, sometimes near the N terminus close to an
N-myristoylation site. An example is dually acylated protein
HASPB, amember of a family of hydrophilic acylated surfacepro-
teins important for parasite development in the insect vector
(Sadlova et al., 2010). HASPB is unusual for an N-myristoylatedChemistprotein in being localized to the outer leaflet of the plasma mem-
brane in infective stages (Dennyet al., 2000;Maclean et al., 2012).
Similarly, SMP-1, one of several small myristoylated proteins, is
flagellum-targeted by acylation (Tull et al., 2004). The SMPs are
targeted to different subcellular compartments depending on
N-terminal acylation and other sequencemotifs (Tull et al., 2012).
Global profiling of protein lipidation in living cells by standard
biochemical methods is challenging. We and others have
made use of bioorthogonal labeling chemistries such as the cop-
per-catalyzed cycloaddition of an alkyne and azide (CuAAC) to
capture proteins metabolically tagged with alkyne or azide fattyry & Biology 22, 342–354, March 19, 2015 ª2015 The Authors 343
acids (Grammel and Hang, 2013). In this approach, fatty acid an-
alogs bearing the biologically inert azide or alkyne functional
group are incubated with cells in culture and incorporated by
cellular machinery into lipidated proteins. Following cell lysis,
proteins can be functionalized via CuAAC with useful groups
such as a fluorophore for visualization by in-gel fluorescence
and a biotin affinity handle for enrichment, enabling subsequent
mass spectrometry analysis and identification of modified pro-
teins. Here, we use an alkyne-tagged myristate analog, YnMyr
(tetradecynoic acid, Figure 1A), which has been previously
used as a mimic for myristic acid in several systems, including
mammalian cells (Thinon et al., 2014) and Plasmodium falcipa-
rum (Wright et al., 2014), to profile the lipidome of L. donovani.
We further combine this chemical proteomic tool with small
molecule NMT inhibitors to confirm target engagement inside
live parasites, and to define the complement of NMT substrates.
RESULTS
YnMyr Tags Proteins in L. donovani
We first sought to demonstrate that YnMyr can tag proteins in
Leishmania, since this has not previously been reported. Meta-
bolic tagging of Ld promastigotes with 50 mM YnMyr followed
by CuAAC with biotin and fluorophore-functionalized reagent
AzTB (Figures 1 and S1) gave several distinct fluorescent bands,
and a diffuse smear between 18–30 kDa (Figure 1B). This diffuse
labeling was effectively removed by CHCl3/MeOH precipitation
or treatment with strong base and was resistant to pronase
digestion (Figures 1B and 1C), suggesting YnMyr incorporation
into a nonprotein component. Leishmania species synthesize
complex glycolipid macromolecules, including glycosylphos-
phatidylinositol (GPI)-anchored proteins, glycoinositol phos-
pholipids (GIPLs), and the complex glycoconjugate lipophos-
phoglycan (LPG) (Ferguson, 1997). Since these molecules
contain acyl-fatty acids or ether-linked alkyl chains, YnMyr incor-
poration into such molecules is not unexpected; indeed, myris-
tate is known to be incorporated into GIPLs and the GPI anchors
of some proteins (Etges et al., 1986; Ralton et al., 2002). In addi-
tion to removal of the diffuse band, treatment with base in pro-
mastigotes resulted in loss of several other bands (Figure 1B).
A well-studied protein in Leishmania is the surface protease
GP63, which incorporates myristic acid into its GPI anchor
(Etges et al., 1986). Consistent with this, GP63 could be detected
after pull-down of YnMyr tagged promastigote lysate onto strep-
tavidin beads (Figure S1). Hydroxylamine treatment of lysates
gave a slight reduction in signal intensity of several weak bands,
suggesting that YnMyr may also be incorporated into some
S-acylation sites (Figure S1).
Labeling in promastigotes was time dependent, outcompeted
by myristic acid and inhibited in the presence of the protein syn-
thesis inhibitor cycloheximide (Figure S1), showing that YnMyr
incorporation is dependent on de novo protein synthesis. Inter-
estingly, although azido-myristate AzMyr produced a similar,
but not identical, labeling pattern, this analog did not label the
diffuse bands (Figure 1D), suggesting that the biosynthetic path-
ways incorporating the analog into these molecules may be less
tolerant to modifications in the lipid structure. The background
labeling generated by CuAAC with YnTB, the alkyne version of
the AzTB capture reagent, was also higher (Figure 1D), as has344 Chemistry & Biology 22, 342–354, March 19, 2015 ª2015 The Aubeen noted previously by others (Charron et al., 2009). These
data suggest that YnMyr is the more suitable probe for labeling
in Leishmania. Longer chain palmitic acid analog YnPal showed
a distinct labeling pattern to the myristate analogs (Figure 1D),
indicating that fatty acyl chain length is important for protein lip-
idation in these cells.
Metabolic tagging with YnMyr in the amastigote stage gave a
distinct labeling pattern compared with promastigotes and no
diffuse bands (Figure 2A). While GIPLs are expressed in both
life cycle stages, LPG andGPI-anchored proteins are downregu-
lated in the amastigote stage (McConville and Blackwell, 1991),
suggesting that the diffuse labeling observed in promastigotes is
related to specific glycolipid biosynthetic pathways. Known
N-myristoylated protein HASPB (Alce et al., 1999) could be de-
tected by western blot after pull-down of tagged proteins onto
streptavidin beads in both life stages (Figure 2A), although the
overall incorporation of YnMyr into HASPB was low, as may be
expected given that the tagged analog competes for substrates
with endogenous lipid. To confirm the nature of HASPB labeling,
YnMyr tagging was performed in L. major strains expressing a
fusion protein consisting of GFP fused to either the N-terminal
18 residues of HASPB (wild-type [WT] 18AA-HASPB-GFP), or
to a mutant in which the N-terminal glycine was mutated to
alanine (G2A) (Denny et al., 2000). The global labeling pattern
was similar between these strains and comparable with that in
L. donovani (Figure S1). Following enrichment of YnMyr tagged
proteins, GFP was detected in the WT sample but not in the
G2A mutant, consistent with canonical attachment of YnMyr to
the N-terminal glycine by NMT; endogenous HASPB was en-
riched from both WT and G2A mutants (Figure 2B).
The freshly harvested ex vivo amastigotes used in the current
study are a practical model system for studying the host infective
stage of Leishmania, but methods to study this intracellular para-
site in its native environment inside mammalian macrophages
would be particularly useful for future host-parasite studies. To
establish whether YnMyr can penetrate the amastigote inside
the parasitophorous vacuole, macrophages infected with Ld
amastigotes were incubated with YnMyr for 18 hr, lysed, and
samples analyzed by gel; uninfected macrophages were used
as a control. Strong labeling of macrophage proteins dominated
in-gel fluorescence of both infected and uninfected samples, as
might be expected from the low multiplicity of infection (10) of
this intracellular model (Figure 2C). HASPB was immunoprecip-
itated (IP) from lysates and incubated with CuAAC reagents on-
bead, followed by protein elution and analysis by western blot.
HASPB was present only in infected samples, as expected,
and a fluorescent band was also visible specifically in YnMyr
tagged samples at the same molecular weight (Figure 2D). This
IP-click approach, which also allows for detection of tagged
HASPB in ex vivo amastigote samples (Figure 2E), circumvents
the challenges posed by the relatively low abundance of parasite
relative to host cell material. These data show that YnMyr also
tags the N-myristoylated protein HASPB in the context of Leish-
mania-infected macrophages.
Global Proteomic Identification of YnMyr Tagged
Proteins in Promastigotes and Amastigotes
Validating the tagging of specific proteins by western blot, as
shown above for HASPB, is a low-throughput method andthors
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Figure 2. YnMyr Tags Known N-Myristoylated Protein HASPB
(A) HASPB is labeled in promastigotes and amastigotes. Parasites were tagged with myristic acid or YnMyr, proteins labeled via CuAAC with AzTB, and a portion
enriched by pull-down (PD) onto streptavidin beads. Four-fold more sample loaded after PD compared with before. Western blot (WB) revealed that HASPB is
specifically enriched in the YnMyr samples.
(B) HASPB is labeled on the N-terminal glycine. L. major parasites expressing the HASPBN terminus (18 residues;WT) fused toGFP or a G2Amutant were tagged
with YnMyr and processed as above. Top: WB for GFP shows that only theWT protein and not the G2Amutant is tagged. Bottom: endogenous HASPB is tagged
in both samples.
(C) In-gel fluorescence analysis of YnMyr tagged proteins from macrophages infected with L. donovani or cultured alone.
(D) HASPB is tagged in intracellular amastigotes. HASPBwas immunoprecipitated (IP) from lysates derived from infected or uninfectedmacrophages taggedwith
YnMyr, and beads incubated with CuAAC reagents. In-gel fluorescence (top) shows a YnMyr- and infection-specific band at the expected migration for HASPB
(arrow). WB (bottom) shows that HASPB (arrow) is present only in infected samples. * indicates antibody IgG heavy chain.
(E) HASPB IP and CuAAC using ex vivo amastigotes.dependent on the availability of an antibody for the protein of in-
terest. To carry out the global identification of YnMyr tagged pro-
teins, Neutravidin-enriched proteins were digested on-bead with
trypsin and peptides analyzed via liquid chromatography-tan-
dem mass spectrometry (LC-MS/MS). For the MS experiments,
a capture reagent (AzRB, Supplemental Experimental Proce-
dures) containing a trypsin-cleavable motif between the azideChemistand biotin groups was designed and used. We have previously
used similar reagents to facilitate release of YnMyr-modified
peptides from Neutravidin beads for identification (Thinon
et al., 2014). A label-free quantification (LFQ) approach (Cox
et al., 2014) was used to assess enrichment over myristic acid
controls. The nature of an enrichment experiment means that
hits are often not detected in controls, and analysis of the datary & Biology 22, 342–354, March 19, 2015 ª2015 The Authors 345
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Figure 3. Proteomic Analysis of YnMyr Tagged Proteins in Leishmania
(A) Volcano plot showing the results of a two-sample t test (FDR 0.05, S0 1) applied to amastigote LFQ intensities to assess enrichment in YnMyr samples over
myristic acid controls (myr). MG, sequence contains an N-terminal glycine; high confidence, significant and absent from myr controls; low abundance, not
significant in the t test but absent from controls; other significant, significant at FDR 0.05 but also detected in myr controls; other, other proteins identified. See
also Figure S2.
(B) Comparison of YnMyr intensities of amastigote and promastigote hits (t test significant and low abundance hits) by t test (FDR 0.05, S0 2) after imputation of
missing values. Proteins are color coded to indicate those containing an N-terminal glycine (MG) and those found in only one of promastigote (Pro.) or amastigote
(Am.) data sets.
(C) Heatmap of YnMyr intensities across replicates for those MG proteins significantly differing between Am. and Pro.was approached in twoways. First, values for missing LFQ inten-
sities were imputed from a normal distribution to simulate values
at the lower limit of detection and a permutation-corrected (false
discovery rate, FDR) t test was applied to define significance
(Figure 3A; Figure S2). Second, the absence of a protein from
controls was considered. Proteins were defined as high confi-
dence hits if they reached significance in the t test and were
absent from controls, while a protein was defined as a low abun-
dance hit if it was absent from controls but did not reach statis-
tical significance due to low intensity in the YnMyr samples. This346 Chemistry & Biology 22, 342–354, March 19, 2015 ª2015 The Aulatter group is more likely to contain false positives in addition to
true hits.
In amastigotes, 81 proteins were significantly enriched (FDR
0.05) and, of these, 49 proteins were assigned as high confi-
dence using the definition above. A further 20 proteins were clas-
sified as low abundance hits (Table S1). In promastigotes, 134
proteins were significantly enriched (FDR 0.01) and, of these,
113 were high confidence; 28 proteins were assigned as low
abundance (Table S2). Notably, 59% of high confidence hits in
amastigotes did not contain an N-terminal glycine (MG),thors
proposed to be a prerequisite of NMT-dependent myristoylation.
In promastigotes, this figure rose to 78%, suggesting that YnMyr
may not exclusively tag N-myristoylated proteins in Leishmania.
However, a number of proteins were indeed detected for which
there is prior experimental evidence for N-myristoylation in
Leishmania, including ARL1 (Sahin et al., 2008), SMP-1 (Tull
et al., 2004), CAP5.5 (Hertz-Fowler et al., 2001), and PPEF (Mills
et al., 2007). Other identifiedMG proteins include other ARF/ARL
proteins, Golgi reassembly stacking protein GRASP, several
other calpain-like cysteine peptidases, and protein phospha-
tases/kinases.
Probable integral membrane proteins were prominent in the
non-MG data sets; of the 107 significant non-MG hits in promas-
tigotes, 57 had predicted transmembrane (TM) helices, and of
the 58 non-MG hits in amastigotes, 28 had this feature (Tables
S1 and S2). Conversely, only 3 MG proteins across both data
sets had a predicted TM domain. S-Palmitoylation of TM pro-
teins is well known to occur in other eukaryotes (Blaskovic
et al., 2013) and it is possible that YnMyr is incorporated
into these proteins by palmitoyltransferases. Indeed, bio-
informatic analysis of the protein sequence suggested that
many hits that lacked the MG motif could be S-palmitoylated
(Figure S2; Table S3). Putative GPI-anchored proteins were
enriched by YnMyr tagging, including five uncharacterized pro-
teins (LdBPK_331200.1, LdBPK_352190.1, LdBPK_090690.1,
LdBPK_364340.1, LdBPK_350860.1), three surface antigens
(LdBPK_050900.1, LdBPK_051210.1, LdBPK_040180.1), and a
putative vacuolar-type proton translocating pyrophosphatase
(Table S3).
Comparison of hits (defined as proteins significantly enriched
over myristic acid controls or low abundance hits) in the two
L. donovani life stages showed high overlap of 67% (Table S3).
A t test was used to compare the YnMyr LFQ intensities of hits
(Figure 3B) revealing that select MG proteins are differentially ex-
pressed. Proteomic studies have revealed changes related to
the transition from promastigote to amastigote stage, in partic-
ular an increase in proteins associated with gluconeogenesis
and mitochondrial metabolism in amastigotes (Biyani and Mad-
hubala, 2012; Rosenzweig et al., 2008). The most strongly differ-
entially regulated putative N-myristoylated proteins identified
here are mostly proteins of unknown function, apart from
SMP-1 and sodium stibogluconate resistance protein, enriched
in promastigotes, and a putative protein kinase found only in
amastigotes (Figure 3C). Overall, likely N-myristoylated proteins
with important functions including transport, protein (de)phos-
phorylation, proteasomal degradation, and Golgi function are
conserved in both Leishmania life stages.
Chemical Knockdown of N-Myristoylation Defines NMT
Substrates
Although the global proteomic approach identified a number of
likelyN-myristoylated proteins, the complexity of YnMyr labeling
in Leishmania complicates the firm assignment of specific pro-
teins as NMT substrates. We therefore sought to use chemical
knockdown of NMT in combination with YnMyr tagging to distin-
guish those proteins that are N-myristoylated from other lipi-
dated proteins, an approach recently used to define substrates
of the human NMTs in cancer cells (Thinon et al., 2014). Com-
pound 1 (Figure 4A) was first reported as a T. brucei NMT inhib-Chemistitor with in vivo efficacy in a rodent model of trypanosomiasis
(Brand et al., 2012; Frearson et al., 2010), and we have subse-
quently shown that this inhibitor also acts on-target to inhibit
NMT in malaria parasites (Wright et al., 2014) and human cancer
cell lines (Thinon et al., 2014). Compound 1 has aKi
(app) (apparent
inhibition constant) of 2.5 nM against LdNMT and EC50s (half
maximal effective concentrations) of 7 mM and 23 mM against
Ld amastigotes and promastigotes, respectively (Paape et al.,
2014). Parasites were preincubated with 1 for 1 hr at varying con-
centrations and then YnMyr was added for 12 hr. Following
CuAAC, a drop in intensity in specific bands could be observed
in both life stages in response to inhibitor (Figures 4B and 4C).
Many bands were completely unaffected, possibly because
these proteins are not tagged via NMT activity, consistent with
the proteomic analyses above suggesting that YnMyr does not
label only N-myristoylated proteins. Blotting for HASPB after
pull-down revealed a dose-dependent decrease in the YnMyr
tagging of this protein (Figures 4B and 4C). These data suggest
that compound 1 inhibits NMT inside the cell.
While 1 translates very poorly from enzyme to cellular potency,
analog 2 shows similar enzyme inhibitory activity but is nearly 50-
fold more potent in the amastigote growth inhibition assay (Fig-
ure 4A). We hypothesized that this contrast could be explained
by the distinct physicochemical properties of the compounds,
which can affect uptake, efflux, and metabolism, or by off-tar-
gets of 2. Incubation with 2 at a concentration around its EC50
(0.2 mM) gave a similar decrease in YnMyr labeling to that
observed at the EC50 of 1 (7 mM) (Figure 4D), suggesting that
despite very different translation from recombinant enzyme to
cell potency, both inhibitors engage NMT inside the cell. As ex-
pected, a lower concentration of 1 (0.2 mM) resulted in only a par-
tial loss of specific labeling.
Inhibited samples were subject to pull-down, digest, and LC-
MS/MS. Biological and technical reproducibility of LFQ inten-
sities across replicates was high (R2 0.76–0.96 after imputation
of missing values; Figure S4) and the 580 proteins present in bio-
logical duplicates in the YnMyr samples were selected for further
analysis (Table S4). After filtering out nonspecific binders,
missing values were imputed. ANOVA (Benjamini Hochberg
correction, FDR 0.001) was used to compare across all four con-
ditions (YnMyr, 0.2 mM 2, 0.2 mM 1, and 7 mM 1) and permutation-
corrected t tests were used to compare each inhibition condition
with YnMyr controls. In all analyses therewas a significant reduc-
tion in intensity in a subset of MG proteins (Figure 5A; Table S4;
Figure S5). Relative to the YnMyr control, 30 proteins in the 7 mM
1 data set were significantly reduced and all contained an N-ter-
minal glycine.
Several bioinformatic tools (Bologna et al., 2004;Maurer-Stroh
et al., 2002) have been developed to predict N-myristoylation.
However, these tools are based on learning sets derived from
other eukaryotes and, of the MG proteins identified here as en-
riched through YnMyr tagging, the predictors disagreed on
whether a protein was a substrate in 30% of cases (Table S5).
In addition, several high confidence hits were assigned as non-
myristoylated by both tools, underlining the value of experi-
mental approaches to test bioinformatic predictions.
For those hits detected and assigned as significant at both
concentrations of inhibitor 1, there was a clear dose-dependent
decrease in intensity in response to 1 (Figure 5C). Several MGry & Biology 22, 342–354, March 19, 2015 ª2015 The Authors 347
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Figure 4. Effect of NMT Inhibition on YnMyr
Tagging
(A) Structures of inhibitors 1 and 2 and summary
of their activity against recombinant LdNMT
(apparent inhibition constant, Ki
(app)) and against
promastigotes (Pro.) or ex vivo amastigotes (Am.)
(half maximal effective concentration, EC50).
(B) Gel-based analysis of YnMyr tagging in pro-
mastigotes treated with inhibitor 1. Top: in-gel
fluorescence showing the effect of increasing 1
concentrations. Bottom: western blot (WB) of
HASPB following enrichment of YnMyr tagged
proteins by pull-down (PD) onto streptavidin
beads.
(C) Gel-based analysis of YnMyr tagging in
amastigotes treated with inhibitor 1. Top: in-gel
fluorescence showing the effect of increasing 1
concentrations. Bottom: WB of HASPB following
enrichment of YnMyr tagged proteins by PD onto
streptavidin beads.
(D) In-gel fluorescence analysis of YnMyr tagging
in amastigotes treated with inhibitor 1 or 2. Arrow
indicates most prominent loss of YnMyr tagging
upon inhibition. Full blots and Coomassie gels are
shown in Figure S3.proteins showed no response and a subset of hits were signifi-
cantly decreased only at the higher concentration (7 mM) of 1
(Table S4). This latter group may contain proteins that are less
sensitive to NMT inhibition, possibly higher affinity substrates
(Thinon et al., 2014). Other proteins (Figure 5D) also did not
show strong responses to 1 and 2. All 16 proteins significantly
affected by inhibitor 2 were also hits in the 1 data set (Figure 5B;
Table S4). However, comparing the LFQ intensities of hits qual-
itatively and via a t test indicated that in fact 0.2 mM 2 did not
inhibitN-myristoylation as effectively as 7 mM 1 (Figure S5). A po-
tential explanation for this result is that 2 does inhibit NMT in
amastigotes but may have additional off-target effects that
slightly increase its potency in cells.
Since 7 mM 1 resulted in the strongest response, this data set
was used in combination with visual examination of heatmaps
to define high and low confidence hits (Table 1; Table S4; Fig-
ure 6A). All 30 proteins significant in the t test were defined as
high confidence NMT substrates since they showed either a
dose-response relationship or were absent from inhibited sam-
ples. Lowconfidence hitswere defined as those not reaching sig-
nificance in the t test but alsonot detected in the inhibited sample,
and include proteins expected to be N-myristoylated such as
GRASP, a calpain, and a serine/threonine phosphatase, but
also four proteins that havenoN-terminalMGmotif andsoareun-348 Chemistry & Biology 22, 342–354, March 19, 2015 ª2015 The Authorslikely to be myristoylated. Of the 30 high
confidence proteins, 18 had been identi-
fied as significant or low abundance hits
in the global amastigote analysis, but a
further 11 had been identified in only one
or two replicates (Table S1), highlighting
the value of employing additional tools
to explore such complex samples.
To provide further insight into the
YnMyr modification of proteins, we usedthe trypsin-cleavable site in AzRB to enable direct identification
of YnMyr-modified peptides. De novo-aided sequencing (Zhang
et al., 2012) was used to search for peptides containing the
YnMyr-AzRB-derived adduct at their N terminus. A total of 20
proteins were detected with this modification on a glycine resi-
due corresponding to the N terminus of the protein (Table S6),
and no peptides were identified in searches of myristic acid con-
trols. Of these 20 proteins, 8 had been identified as high confi-
dence NMT substrates via quantification of their response to
NMT inhibition and include known N-myristoylated protein
LdARL1, a proteasome subunit, a PP2C-like protein, a predicted
protein kinase and four uncharacterized proteins (Tables 1 and
S6; Figure 6A). An additional four lower confidence substrates
were also modified. Interestingly, modification on the N-terminal
glycine of three proteins (two fatty acyl-CoA ligases and unchar-
acterized LdBPK_300680.1) that did not respond robustly to
NMT inhibition was detected; these proteins may be NMT sub-
strates that are additionally modified elsewhere, for example,
at their enzyme active site or at alternative sites, or may bemodi-
fied on their N terminus by a mechanism distinct from NMT.
Several other modified proteins were identified that had not
been included in the global analyses due to weak detection.
Gene ontology analysis of the 30 high confidence NMT sub-
strates revealed that they have diverse functions and include
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Figure 5. Proteomics Analysis of YnMyr
Tagged Proteins in Amastigotes Treated
with NMT Inhibitors
(A) ANOVA test (Benjamini Hochberg correction,
FDR 0.001) applied to LFQ intensities to compare
inhibition conditions. The fold change in response
to 7 mM 1 is plotted against log10(p value). Pro-
teins above the dashed line reached significance
in this test. MG, sequence contains an N-terminal
glycine. Volcano plots of two-sample t tests are
shown in Figure S5.
(B) Comparison of LFQ ratios for 0.2 mM 2 and
7 mM 1 data sets after removal of nonspecific
binders. The proteins assigned as significantly
affected by both inhibitors are indicated. See
Figure S5 for direct comparison of these ratios by
t test.
(C) Response of selected MG proteins to 0.2 and
7 mM 1. Mean LFQ intensity before imputation of
missing values is plotted.
(D) MG proteins where YnMyr tagging does not
respond to NMT inhibition.phosphatases and kinases, proteins involved in transport and
degradation, as well as many (50%) proteins of unknown func-
tion (Figure 6B).
DISCUSSION
Here we combine chemical proteomic tools with inhibitors and
quantitative mass spectrometry to define the complement of
N-myristoylated proteins in L. donovani parasites, and explore
NMT as a potential drug target in this important human path-
ogen. Proteomic and gel-based analyses reveal that YnMyr is
incorporated into diverse sets of proteins, including N-myris-
toylated and GPI-anchored proteins, as well as into what are
most likely complex glycolipids. YnMyr incorporation into pro-
teins other than NMT substrates is not unprecedented; for
example, we observed significant YnMyr tagging of GPI-
anchored proteins in malaria parasites (Wright et al., 2014).
However, the proteomic analyses carried out here suggest
that while YnMyr does tag GPI-anchored proteins in Ld, these
are by no means the most abundant hits. A possibility is incor-
poration into S-acylation sites, since in mammalian cells YnMyr
and similar probes label both N-myristoylated and S-palmitoy-
lated proteins (Charron et al., 2009; Thinon et al., 2014) and
palmitoyltransferases have varying acyl-CoA specificities (Jen-
nings and Linder, 2012). Alternatively, YnMyr may be metabo-
lized to longer or shorter chain analogs retaining the alkyne
tag that are subsequently incorporated into proteins, or it
may be that alternative lipid modifications, such as the poorly
characterized lysine N-acylation (Lin et al., 2012), are prevalentChemistry & Biology 22, 342–35in Leishmania. Although enzymes with
lysine deacylase activity have been
described (Jiang et al., 2013), those
that carry out lysine acylation have not
been identified and it has been sug-
gested that such modifications may in
fact be nonenzymatic (Wagner and Hir-
schey, 2014). Leishmania may metabo-lize YnMyr to a reactive intermediate that nonenzymatically
modifies proteins.
In addition to identification of lipidated proteins, we provide
evidence that compounds 1 and 2 inhibit NMT in live parasites.
While the potent in vitro activities of these compounds translate
to cellular activity rather poorly, and to very different extents, we
show here that this activity is accompanied by a drop in N-myr-
istoylation levels of specific proteins and thus provide the first
direct evidence for the druggability of NMT in Leishmania. Prob-
lems with translation from enzyme to cellular assays have been
reported previously in Leishmania, particularly in amastigotes
(Walker et al., 2011), but we anticipate that the methodology
developed here will be useful for screening NMT inhibitors for
target engagement inside the cell. Further experiments are
now required to confirm that the antiparasitic effects of inhibitors
1 and 2 arise solely through inhibition of NMT, and to identify
which NMT substrates mediate these effects.
The depth of coverage of the YnMyr tagged proteome identi-
fied could be improved; for example, HASPB, despite being de-
tectably tagged in gel-based analyses, was not identified in MS
studies; this may be due in large part to the sequence of this pro-
tein, which contains multiple repeats and is highly hydrophilic.
Several possible NMT substrates were detected but did not
meet the stringent filtering criteria applied and it is thus likely
that more NMT substrates remain to be validated in the future.
The set of proteins assigned as NMT substrates here is gener-
ally consistent with previous literature on N-myristoylated pro-
teins in Leishmania and other eukaryotes. Surprisingly, the
lipidation levels of CAP5.5 did not respond to inhibition of NMT4, March 19, 2015 ª2015 The Authors 349
Table 1. High and Low Confidence NMT Substrates Identified by Quantitative Proteomics with YnMyr in Combination with NMT
Inhibitors
Mean log2(LFQ intensity) is given and cells are color coded based on value. NaN, not a number (not found); Sig., significant. Proteins for which the
YnMyr-modified N terminus was detected are indicated. See also Tables S4 and S6.
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Figure 6. Analysis of Proteins whose Acylation Responds to NMT
Inhibitors
(A) Enrichment over myristic acid (Myr) control compared with response to
inhibitor (7 mM 1) for hits. High confidence, significantly affected by inhibition
(t test FDR 0.001); low confidence, not detected in inhibitor-treated samples
but not significant in the t test due to low intensity in the YnMyr controls.
Proteins for which YnMyr modification on the N-terminal glycine was detected
are indicated (see also Table S6).
(B) GO annotation (TriTrypDB) of 30 high confidence NMT substrates.(Figure 5D; Table S4). CAP5.5 contains a strongly predictedmyr-
istoylation motif (Table S5) and its ortholog has been shown
experimentally to be N-myristoylated and S-palmitoylated in
T. brucei, the latter presumably on a nearby cysteine residue
(Hertz-Fowler et al., 2001). Similarly, although the phosphatase
PPEF did respond to NMT inhibition, basal YnMyr tagging was
still detectable (Table 1). There is evidence that PPEF is dually
acylated in L. major, with palmitoylation being dependent on
myristoylation, suggesting that in the absence of myristoylation
no labeling should occur (Mills et al., 2007). It is possible that
the relatively high concentration of YnMyr used here could force
incorporation into S-acylation or other sites, or that experimental
differences between studies may account for these different re-
sults; the dynamic nature of S-acylation may render labeling
highly dependent on incubation time and other culture condi-
tions. Alternatively, we cannot exclude the existence of another
enzyme with acyltransferase activity that carries out N-terminal
N-lipidation in Leishmania, although no experimental or bio-
informatic evidence has yet been reported to suggest this, and
there is no evidence for compensation on deletion of NMT in pro-
mastigotes (Brannigan et al., 2010).ChemistJust over half of the 30 high confidence NMT substrates iden-
tified here are uncharacterized proteins, highlighting the huge
amount of NMT-related biology yet to be explored in Leishmania.
However, some predictions for the outcome of NMT inhibition
can be drawn from these data. ARF/ARL proteins, of which five
were identified as strongly affected by NMT inhibition, are impor-
tant mediators of intracellular trafficking in all eukaryotes and
their specific localization is often dependent onN-myristoylation.
LdARL1 is localized to the trans-Golgi network and involved in
control of endocytosis (Sahin et al., 2008); its T. brucei homolog
is also a Golgi protein essential in bloodstream parasites, where
its depletion causes defects in exocytosis and Golgi structure
(Price et al., 2005). TbARL6 is involved in flagellum extension,
interaction with microtubules, and the BBSome (Price et al.,
2012), which is important for specific trafficking events in all eu-
karyotes and is essential for virulence in Leishmania (Price et al.,
2013). Therefore basic cellular functions such as Golgi structure,
endo- and exocytosis are very likely to be affected by inhibition
of NMT, perhaps affecting parasite virulence. The identification
of three protein phosphatases, one kinase and phosphatidylino-
sitol phosphate kinase, suggests that signaling processes
dependent on specific (de)phosphorylation events will also be
disrupted. Finally, the proteasome has already been shown to
be a potential drug target in Plasmodium (Li et al., 2014) and
N-myristoylation of this subunit linked to function in yeast, where
removal of the myristoylation site causes proteasome mislocali-
zation, accumulation of misfolded protein, and growth defects
(Kimura et al., 2012). In summary, these data predict a strongly
pleiotropic effect of NMT inhibition on parasite cellular function
and provide evidence for NMT as a valid drug target in
Leishmania.
SIGNIFICANCE
The leishmaniases are a spectrum of neglected tropical dis-
eases for which few drugs are available and novel ap-
proaches are urgently required. A deeper understanding of
the underlying biology, and chemical validation, of potential
drug targets may improve the chances of successfully
developing new treatments. NMT catalyzes a specific and
essential lipidation of proteins in eukaryotes and the present
study explores protein lipidation in Leishmania donovani,
the causative agent of themost severe form of the leishman-
iases. We take advantage of the global picture afforded by a
chemical proteomic approach using a bioorthogonally
tagged lipid analog to show that protein lipidation in the
parasite is diverse and complex. To overcome this
complexity and identify NMT substrates, we quantify protein
lipidation levels in the presence of NMT inhibitors and sup-
port this with direct lipidation site identification. These
results predict pleiotropic effects of NMT inhibition in para-
sites and provide a method to assay for target engage-
ment in the cell. This work also constitutes the first global
experimental analysis of protein lipidation in Leishmania
and contributes a large proteomic data set for this
neglected human pathogen. These data may provide further
insights into other drug targets, for example, the complex
glycolipid pathways or individual functionally important
NMT substrates.ry & Biology 22, 342–354, March 19, 2015 ª2015 The Authors 351
EXPERIMENTAL PROCEDURES
Supplemental Experimental Procedures
The following procedures were carried out essentially as described previously
and details are given in the Supplemental Experimental Procedures: ex vivo
amastigote inhibition, macrophage cytotoxicity, and enzyme inhibition assays
(Hutton et al., 2014); sample preparation for proteomics analysis and LC-MS/
MS (Thinon et al., 2014).
Chemical Tools
The following chemical tools were synthesized as described previously:
YnMyr, YnPal, and AzTB (Heal et al., 2011); AzMyr and YnTB (Heal et al.,
2012); inhibitors 1 and 2 (Thinon et al., 2014). Synthesis of AzRB is given in
the Supplemental Experimental Procedures. Myristic and palmitic acids,
cycloheximide (CHX), and all other chemicals were purchased.
Ethics Statement
Animal experiments were approved by the University of York Animal Proce-
dures and Ethics Committee and performed under UK Home Office license
(Immunity and Immunopathology of Leishmaniasis Ref. no. PPL 60/3708).
Parasite Culture
The Ethiopian LV9 strain of Leishmania donovani (MHOM/ET/67/L28) was
maintained by serial passage in Rag-2/ mice. Amastigotes were extracted
from spleen as described previously (Smelt et al., 1997) and cultured in
RPMI/10% fetal calf serum (FCS). Promastigotes were obtained by transform-
ing 1 3 107 freshly isolated amastigotes in promastigote medium (St-Denis
et al., 1999) at 26C (2 days for transformation). Promastigotes were
passaged twice a week for up to 10 passages. Further details are given in
the Supplemental Experimental Procedures.
Metabolic Tagging Experiments
Promastigotes were cultured in RPMI/10% FCS containing the appropriate
probe (50 mM YnMyr, myristic acid, or as indicated) at a parasite density of
7.5 3 107 parasites/ml. Cultures were incubated at 26C for 12 hr (or as indi-
cated). Cells were collected (800 3 g, 15 min, 4C), washed twice with cold
PBS, then lysed at 1 3 109 parasites/ml by sonication on ice (4 3 10 s burst,
amplitude 45 with 1 min interval) in 1% NP40, 1% sodium deoxycholate,
0.5% SDS, 50 mM Tris (pH 7.4), 150 mM NaCl, EDTA-free protease inhibitor.
Insoluble material was separated by centrifugation (16,100 3 g, 30 min, 4C).
Tagging of ex vivo amastigotes was carried out as above but parasites were
cultured at 37C. For inhibition studies, the appropriate inhibitor was preincu-
bated with parasite culture for 1 hr at 37C, parasites pelleted and resus-
pended in fresh medium containing inhibitor plus probe (YnMyr etc). Further
details are given in the Supplemental Experimental Procedures.
Intracellular Amastigote Tagging
BALB/c mice were obtained from Charles River. Macrophages (BMDM) were
differentiated from bone marrow of BALB/c mice as described previously
(Weinheber et al., 1998) andplatedout at 13106 cells perwell in six-well plates.
BMDMswereadheredovernightand then infectedat amultiplicityof infectionof
10 with freshly isolated L. donovani amastigotes (see above). After 24 hr no free
parasites were observed. Tagging was performed for 18 hr with YnMyr or myr-
istic acid at a final concentration of 100 mM.Cells werewashed three timeswith
PBS at room temperature (RT) before 300 ml of lysis buffer was added and cells
scraped off. The lysate was sonicated (33 10 s, amplitude 45 with 1 min inter-
vals), then centrifuged for 30 min at 16,100 3 g at 4C. The supernatant was
transferred into a fresh tube and flash frozen in liquid nitrogen. BMDMs were
maintained in DMEM supplemented with 4 mM L-glutamine and 4% L929-
cell conditionedmedium.All experimentswereperformedat 37Cand5%CO2.
CuAAC Labeling and Pull-down
Proteins were precipitated with chloroform/methanol (MeOH:CHCl3:ddH2O
4:1:3), or acetone (4 volumes at 20C for 1 hr) and then resuspended at
1 mg/mL in 1% SDS in PBS. This precipitation step was found to increase
labeling intensity after CuAAC. Premixed click reagents (100 mM AzTB,
1 mM CuSO4, 1 mM TCEP, 100 mM TBTA, final concentrations) were added
(Heal et al., 2012) and samples vortexed for 1 hr at RT, then quenched by352 Chemistry & Biology 22, 342–354, March 19, 2015 ª2015 The Authe addition of 10 mM EDTA. Proteins were precipitated again with MeOH/
CHCl3 or with 10 volumes of MeOH (overnight at 80C), washed with ice-
cold MeOH, air-dried, and resuspended in 2% SDS, 10 mM EDTA in PBS.
For direct gel analysis, 43 sample loading buffer (NuPAGE LDS sample buffer)
with 2-mercaptoethanol (4% final) was added. For hydroxylamine (NH2OH)
and NaOH treatment, samples were treated with 1 M NH2OH (pH 7) or 0.2 M
NaOH at RT for 1 hr. Samples were quenched by addition of 43 sample
loading buffer. Note that addition of EDTA to the samples before NH2OH treat-
ment is important to avoid sample degradation. Proteins were heated for 3 min
at 95C prior to SDS-PAGE. Pull-down was carried out with Dynabeads
MyOne Streptavidin C1 as described previously (Wright et al., 2014) (see Sup-
plemental Experimental Procedures).
Gel and Western Blot Analysis
Samples were separated by SDS-PAGE and scanned with Cy3 filters to detect
the TAMRA fluorophore using an Ettan DIGE scanner (GE Healthcare).
For western blot, proteins were transferred from gels to polyvinylidene fluo-
ridemembrane (Immobilon-PSQ,Millipore) using a semidry system (Invitrogen).
Following blocking (5% milk in Tris-buffered saline, 1% Tween), membranes
were incubated with primary antibody for 1 hr at RT or overnight at 4C in
blocking solution, then incubated with secondary antibody (goat anti-rabbit
IgG-HRP, Invitrogen, 1:10,000) for 1 hr in blocking solution. Detection was
carried out using Luminata Crescendo Western HRP substrate (Millipore) ac-
cording to the manufacturer’s instructions and on a Fujifilm LAS 3000 imager.
Primary antibodies, LdHASPB (rabbit; ab 2-AE) (Alce et al., 1999), LmHASPB
(rabbit, 336) (Alce et al., 1999), GP63 (rabbit, polyclonal; provided by
R. McMaster, University of British Columbia) (Frommel et al., 1990), GFP
(mouse, Santa Cruz), were used at 1:1,000–2,000.
Proteomic Data Searching and Analysis
Data Searching and Analysis
The data were processed with MaxQuant version 1.3.0.5 and the peptides
were identified from the MS/MS spectra searched against The TriTrypDB-
6.0 L. donovani LdBPK282A1 database using the Andromeda search engine.
The protein HASPB was not present in this database and so the Uniprot
sequence (O77300_LEIDO) was appended to the FASTA file. Cysteine carba-
midomethylation was used as a fixed modification and methionine oxidation
and N-terminal acetylation as variable modifications. The false discovery
rate was set to 0.01 for peptides, proteins, and sites. Other parameters were
used as preset in the software. ‘‘Unique and razor peptides’’ mode was
selected to allow for protein grouping; this calculates ratios from unique and
razor peptides (razor peptides are uniquely assigned to protein groups and
not to individual proteins). Data were elaborated using Perseus versions
1.4.0.20 and 1.5.0.31. LFQ experiments in MaxQuant were performed using
the built-in label-free quantification algorithm (Cox et al., 2014).
Modified Peptide Identification
MSdata were processed with PEAKS7 suite (Zhang et al., 2012) The data were
searched against a reference L. donovani database fromUniprot (27/11/2014).
Trypsin (specific, up to threemissed cleavages allowed) was selected for data-
base searches and no enzymewas chosen for de novo searches. Themaximal
mass error was set to 5 ppm for precursor ions and 0.01 Da for product ions.
Carbamidomethylation was selected as a fixed modification and methionine
oxidation as well as the lipid-derived adduct (+534.3278 Da) to any amino
acid at peptide N terminus were set as variable modifications. The maximal
number of modifications per peptide was set as five. The false discovery rate
was set to 0.01 for peptides andb1 ionswere required for N-terminallymodified
peptides.Within PEAKS, amodule called SPIDER searches for pointmutations
to further enhance the discovery (Ma and Johnson, 2011).
Data Processing: YnMyr Tagged Proteins in Amastigotes and
Promastigotes
For amastigotes, four replicates were performed independently, starting from
the same metabolically labeled lysates (Myr and YnMyr samples). Data were
filtered to require three valid values across the four replicates, label-free inten-
sities were logarithmized (base 2), and empty values were imputed with
randomnumbers from a normal distribution, whosemean and SDwere chosen
to simulate low abundance values close to noise level (impute criteria: width
0.1, downshift 1.8). A modified t test with permutation-based FDR statistics
was applied (250 permutations; FDR 0.05; S0 1).thors
For promastigotes, three replicates were performed independently, starting
from the same metabolically labeled lysates (Myr and YnMyr samples). Data
were analyzed as described above with three valid values per group
required, imputation (width 0.1, downshift 1.8), and t test (250 permutations;
FDR 0.01; S0 1).
For the comparison of amastigotes and promastigotes, data were filtered for
at least three valid values in at least one group (groups: Am_Myr, Am_YnMyr,
Pro_Myr, Pro_YnMyr). YnMyr intensities of hits (proteins that were either t test
significant or classed as low abundance hits in the independent analyses) were
compared by t test (250 permutations; FDR 0.05; S0 2) after imputation of
missing values (width 0.1, downshift 2.5). Hierarchical clustering was carried
out in Perseus.
Data Processing: YnMyr Tagging in the Presence of NMT Inhibitors
(Amastigotes)
Independent biological experiments were carried out where amastigotes were
incubated with YnMyr, YnMyr + 0.2 mM 2, YnMyr + 0.2 mM 1, or YnMyr + 7 mM
1. A Myr control was included in one of these experiments. For proteomics
analysis, all samples were prepared and processed in duplicate (technical rep-
licates: A and B; C and D). The ‘‘Match between runs’’ option (time window
2 min) in MaxQuant was enabled during the searches. Data were grouped,
filtered to retain only those proteins present in both biological experiments,
and nonspecific binders (enrichment over control <2) removed. Missing values
were imputed from a normal distribution (width 0.1, downshift 1.8) and modi-
fied two-sample t tests were applied (250 permutations; FDR 0.001; S0 1).
ANOVA (Benjamini Hochberg correction, FDR 0.001) was also applied to
LFQ intensities to compare across all data sets.
SUPPLEMENTAL INFORMATION
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